Current approaches to Dengue Virus (DENV) vaccine design all make use of live attenuated viruses. This appraoch suffers from difficulties in desinging a vaccine formulation that can eleicit a balanced immune response against all four serotypes of DENV. Subunit vaccines, composed only of the immungenic E protein found on the surface of the DENV viral capsid, present an alternative appraoch to live attenuated vaccines; however, this appraoch has not been widley tested because it is difficult to express the DENV E protein in dimer form. Our invetigators have developed mutant Dengue E proteins that are stable as dimers in solution, and that can be used in a subunit DENV vaccine that targets all four DENV serotypes.
- Dimerization of dengue virus E-subunits impacts antibody function and domain focus J Virol. 2020 Jul 1;JVI.00745-20